cat no | io1020
ioGlutamatergic Neurons
PRKN R275W/R275W
Human iPSC-derived Parkinson's disease model
ioGlutamatergic Neurons PRKN R275W/R275W are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered homozygous mutation in the PRKN gene encoding the Parkin protein. These cells offer a rapidly maturing, disease relevant and isogenic system for investigating the molecular and cellular significance of a homozygous R275W mutation in Parkinson’s disease.
Place your order
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
Benchtop benefits
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of homozygous expression of mutant Parkin protein on disease.
Scalable
With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Highly characterised and defined
ioGlutamatergic Neurons PRKN R275W/R275W express neuron-specific markers comparably to the isogenic control
Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PRKN R275W/R275W compared to the isogenic control. 100X magnification.
ioGlutamatergic Neurons PRKN R275W/R275W form structural neuronal networks by day 11
.png?width=1715&height=651&name=ioGlutamatergic_neurons-PRKN-R275W-R275W-Morphology%20(1).png)
ioGlutamatergic Neurons PRKN R275W/R275W mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thawing; 100X magnification.
ioGlutamatergic Neurons PRKN R275W/R275W demonstrate gene expression of neuronal and glutamatergic-specific markers following deterministic programming
Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/R275W and the isogenic control (WT) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data expressed relative to the parental hiPSC control (iPSC Control), normalised to HMBS). Data represents day 11 post-revival samples.
Disease-related PRKN is expressed in ioGlutamatergic Neurons PRKN R275W/R275W following deterministic programming
Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/R275W and the isogenic control (WT) express the PRKN gene encoding the Parkin protein. Gene expression levels were assessed by RT-qPCR (data expressed relative to the parental hiPSC control (iPSC Control), normalised to HMBS). Data represents day 11 post-revival samples.
Cells arrive ready to plate
ioGlutamatergic Neurons PRKN R275W/R275W are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
Industry leading seeding density
The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
ioGlutamatergic Neurons
Download
ioGlutamatergic Neurons Wild Type and related disease models | User Manual
Download
Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease
Download
Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons
Download
Running Large-Scale CRISPR Screens in Human Neurons
Watch now
Hoescht(blue)TUBB3(blue)_day4.jpg?width=604&name=bit.bio_ioGlutamatergic%20Neurons_60xMAP2(red)Hoescht(blue)TUBB3(blue)_day4.jpg)
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming
Watch now
Industrialising Cellular Reprogramming: Leveraging opti-ox Technology to Manufacture Human Cells with Unprecedented Consistency
Watch now
Cell culture hacks | human iPSC-derived glutamatergic neurons
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
.png?width=1860&height=1260&name=bit.bio_3x2_ioGlutamatergic%20Neurons_MAP2_Hoescht_x20_hi.res%20(1).png)
ioDisease Model Cells
ioGlutamatergic Neurons PRKN R275W/WT
cat no. io1013
Order now
ioWild Type Cells
ioGlutamatergic Neurons
cat no. io1001
Order now
CRISPR-Ready ioCells
CRISPR-Ready ioGlutamatergic Neurons
cat no. io1090S
Order now
ioDisease Model Cells
ioGlutamatergic Neurons HTT 50CAG/WT
cat no. ioEA1004
Order now
ioDisease Model Cells
ioGlutamatergic Neurons MAPT N279K/WT
cat no. io1009
Order now
ioDisease Model Cells
ioGlutamatergic Neurons MAPT P301S/WT
cat no. io1015
Order now
ioDisease Model Cells
ioGlutamatergic Neurons TDP‑43 M337V/WT
cat no. ioEA1006
Order now
ioDisease Model Cells
ioGlutamatergic Neurons MAPT N279K/N279K
cat no. io1014
Order now
ioDisease Model Cells
ioGlutamatergic Neurons MAPT P301S/P301S
cat no. io1008
Order now
ioDisease Model Cells
ioGlutamatergic Neurons TDP‑43 M337V/M337V
cat no. ioEA1005
Order now
Wild Type and Isogenic Disease Model cells: A true comparison.
Further your disease research by pairing our wild type cells with isogenic disease models.
